Compared with arzoxifene, tamoxifen provides longer progression-free survival and time to treatment failure in women with locally advanced and metastatic breast cancer, according to a report in the November 1st Journal of Clinical Oncology. Reuters Health Information
In this Expert Interview from ASH 2007, Dr. Jorge Cortes discusses new and follow-up data from clinical trials of drug therapies for CML. Medscape Hematology-Oncology
An intensive immunochemotherapy regimen used in a Nordic study shows a plateau in survival curves that suggests a cure is in sight, say researchers. Medscape Medical News